

10/579105

1AP20Rec'd PCT/PTO 12 MAY 2006

INFORMATION DISCLOSURE  
STATEMENT  
Patent Application  
Docket No. SER-108C1

May 12, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beat A. Imhof, Michel Aurrand-Lions  
Docket No. : SER-108C1  
For : Angiogenesis Inhibiting Molecules and Their Use in the Treatment and  
Diagnosis of Cancer

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:


In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted a copy of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

International Publication No. WO 97/07671, cited as F11 on the attached form PTO/SB/08, is written in a foreign language. Applicants are submitting herewith EP 0843961, cited as F12 on the attached form PTO/SB/08, which is believed to be an English language equivalent of International Publication No. WO 97/07671. Applicants note that although the specification of International Publication No. WO 97/07671 is written in a foreign language, an English language Abstract is provided therewith. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of references cited therein

1AP20 Rec'd PCT/PTO 12 MAY 2006

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	2004579105
				Filing Date	May 12, 2006
				First Named Inventor	Beat Albert Imhof
				Art Unit	
				Examiner Name	
Sheet	1	of	5	Attorney Docket Number	SER-108C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2003/0017534	01-23-2003	BUELOW <i>et al.</i>	All
	U2	US-2004/0208873	10-21-2004	TEELING <i>et al.</i>	All
	U3	US-5,545,806	08-13-1996	LONBERG <i>et al.</i>	All
	U4	US-5,545,807	08-13-1996	SURANI <i>et al.</i>	All
	U5	US-5,569,825	10-29-1996	LONBERG <i>et al.</i>	All
	U6	US-5,625,126	04-29-1997	LONBERG <i>et al.</i>	All
	U7	US-5,633,425	05-27-1997	LONBERG <i>et al.</i>	All
	U8	US-5,661,016	08-26-1997	LONGBERG <i>et al.</i>	All
	U9	US-5,712,120	01-27-1998	RODRIGUEZ <i>et al.</i>	All
	U10	US-5,770,429	06-23-1998	LONBERG <i>et al.</i>	All
	U11	US-5,789,650	08-04-1998	LONBERG <i>et al.</i>	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1	WO 03/006673 A2	01-23-2003	Texas Biotechnology Corporation	All	
	F2	WO 00/53749 A2	09-14-2000	RMF Dictagene SA	All	
	F3	WO 2003/008541 A2 (CD-ROM)	01-30-2003	Eli Lilly and Company	All	
	F4	WO 03/59282 (CD-ROM)	07-24-2003	Medarex, Inc.	All	
	F5	WO 01/14424 (CD-ROM)	03-01-2001	Medarex, Inc.	All	
	F6	WO 02/43478 (CD-ROM)	06-06-2002	Medarex, Inc., Kirin Beer Kabushiki Kaisha	All	
	F7	WO 92/03918 (CD-ROM)	03-19-1992	GenPharm International, Inc.	All	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

1AP20 Rec'd PGT/PTO 12 MAY 2006

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/E79105
				Filing Date	May 12, 2006
				First Named Inventor	Beat Albert Imhof
				Art Unit	
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	SER-108C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U12	US-5,814,318	09-29-1998	LONBERG <i>et al.</i>	All
	U13	US-5,874,299	02-23-1999	LONBERG <i>et al.</i>	All
	U14	US-5,877,397	03-02-1999	LONBERG <i>et al.</i>	All
	U15	US-			
	U16	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F8	WO 92/22645 (CD-ROM)	12-23-1992	GenPharm International, Inc.	All	
	F9	WO 93/01227 (CD-ROM)	01-21-1993	University of Massachusetts at Amherst	All	
	F10	WO 94/25585 (CD-ROM)	11-10-1994	GenPharm International, Inc.	All	
	F11	WO 97/07671 (CD-ROM)	03-03-1997	Kirin Beer Kabushiki Kaisha	All	X
	F12	EP 0843961 (CD-ROM)	05-07-1996	Kirin Beer Kabushiki Kaisha	All	
	F13	WO 98/24884 (CD-ROM)	06-11-1999	GenPharm International, Inc.	All	
	F14	WO 99/45962 (CD-ROM)	09-16-1999	GenPharm International, Inc.	All	
	F15	WO 2004/055056 (CD-ROM)	07-01-2004	Merck Patent GMBH	All	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

1AP20Rec'd PTO 12 MAY 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known: 79105		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	86/379105	
			Filing Date	May 12, 2006	
			First Named Inventor	Beat Albert Imhof	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	5	Attorney Docket Number	SER-108C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ARRATE, M.P. <i>et al.</i> "Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor", <i>The Journal of Biological Chemistry</i> , December 7, 2001, pp. 45826-45832, Vol. 276, No. 49.	
	R2	AURRAND-LIONS, M. <i>et al.</i> "JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells", <i>Journal of Biological Chemistry</i> , January 26, 2001, pp. 2733-2741, Vol. 276, No. 4.	
	R3	BAZZONI, G. "The JAM family of junctional adhesion molecules", <i>Current Opinion in Cell Biology</i> , 2003, pp. 525-530, Vol. 15, No. 5.	
	R4	JOHNSON-LÉGER, C. <i>et al.</i> "Junctional adhesion molecule-2 (JAM-2) promotes lymphocyte transendothelial migration", <i>Blood</i> , October 1, 2002, pp. 2479-2486, Vol. 100, No. 7.	
	R5	LIANG, T. W. <i>et al.</i> "Vascular endothelial-junctional adhesion molecule (VE-JAM)/JAM 2 interacts with T, NK, and dendritic cells through JAM 3", <i>Journal of Immunology</i> , 2002, pp. 1618-1626, Vol. 168, No. 4.	
	R6	MULLER, W.A. "Leukocyte—endothelial-cell interactions in leukocyte transmigration and the inflammatory response", <i>Trends in Immunology</i> , June 2003, pp. 326-333, Vol. 24, No. 6.	
	R7	NAIK, M.U. <i>et al.</i> "Signaling through JAM-1 and $\alpha_v\beta_3$ is required for the angiogenic action of bFGF: dissociation of the JAM-1 and $\alpha_v\beta_3$ complex", <i>Blood</i> , September 15, 2003, pp. 2108-2114, Vol. 102, No. 6.	
	R8	VESTWEBER, D. "Regulation of endothelial cell contacts during leukocyte extravasation", <i>Current Opinion in Cell Biology</i> , 2002, pp. 587-593, Vol. 14, No. 5.	
	R9	VESTWEBER, D. "Molecular mechanisms that control endothelial cell contacts", <i>Journal of Pathology</i> , 2000, pp. 281-291, Vol. 190, No. 3.	
	R10	AURRAND-LIONS, M. <i>et al.</i> "Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members", <i>Blood</i> , December 15, 2001, pp. 3699-3707, Vol. 98, No. 13.	
	R11	CHAVAKIS, T. <i>et al.</i> "The junctional adhesion molecule-C promotes neutrophil transendothelial migration <i>in Vitro</i> and <i>in Vivo</i> ", <i>The Journal of Biological Chemistry</i> , December 31, 2004, pp. 55602-55608, Vol. 279, No. 53.	
	R12	CHEN, J. <i>et al.</i> "B cell development in mice that lack one or both immunoglobulin $\kappa$ light chain genes", <i>The EMBO Journal</i> , 1993, pp. 821-830, Vol. 12, No. 3.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

1AP20 Rec'd USPTO 12 MAY 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	404,105	
			Filing Date	May 12, 2006	
			First Named Inventor	Beat Albert Imhof	
			Group Art Unit		
			Examiner Name		
			Attorney Docket Number	SER-108C1	
Sheet	4	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R13	CHEN, J. <i>et al.</i> "Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the J <sub>H</sub> locus", <i>International Immunology</i> , 1993, pp. 647-656, Vol. 5, No. 6.	
	R14	CHOI, T.K. <i>et al.</i> "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome", <i>Nature Genetics</i> , June 1993, pp. 117-123, Vol. 4.	
	R15	CROWTHER, M. <i>et al.</i> "Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors", <i>Journal of Leukocyte Biology</i> , October 2001, pp. 478-490, Vol. 70.	
	R16	CUNNINGHAM, S.A. <i>et al.</i> "A Novel Protein with Homology to the Junctional Adhesion Molecule", <i>The Journal of Biological Chemistry</i> , November 3, 2000, pp. 34750-34756, Vol. 275, No. 44.	
	R17	FISHWILD, D.M. <i>et al.</i> "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice", <i>Nature Biotechnology</i> , July 1996, pp. 845-851, Vol. 14.	
	R18	HARDING, F.A. <i>et al.</i> "Class switching in human immunoglobulin transgenic mice", <i>Annals New York Academy of Sciences</i> , 1995, pp. 536-546, Vol. 764.	
	R19	JONES, P.T. <i>et al.</i> "Replacing the complementarity-determining regions in a human antibody with those from a mouse", <i>Nature</i> , May 29, 1986, pp. 522-525, Vol. 321.	
	R20	JOOSTEN, V. <i>et al.</i> "The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi", <i>Microbial Cell Factories</i> , 2003, pp. 1-15, Vol. 2, No. 1.	
	R21	KOHLER, G. <i>et al.</i> "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> , August 7, 1975, pp. 495-497, Vol. 256.	
	R22	LONBERG, N. <i>et al.</i> "Antigen-specific human antibodies from mice comprising four distinct genetic modifications", <i>Nature</i> , April 28, 1994, pp. 856-859, Vol. 368.	
	R23	LONBERG, N. <i>et al.</i> "Human antibodies from transgenic mice", <i>Intern. Rev. Immunol.</i> , 1995, pp. 65-93, Vol. 13.	
	R24	LONBERG, N. "Transgenic approaches to human monoclonal antibodies", <i>Handbook of Experimental Pharmacology</i> , 1994, pp. 49-101, Vol. 113	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

APPROVED FOR PUBLICATION 12 MAY 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/579105	
			Filing Date	May 42, 2006	
			First Named Inventor	Beat Albert Imhof	
			Group Art Unit		
			Examiner Name		
			Attorney Docket Number	SER-108C1	
Sheet	5	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R25	MERINO, R. <i>et al.</i> "The Yaa gene abrogates the major histocompatibility complex association of murine lupus in (NZB x BXSB)F <sub>1</sub> Hybrid Mice", <i>J. Clin. Invest.</i> , August 1994, pp. 521-525, Vol. 94, No. 2.	
	R26	MORRISON, S.L. <i>et al.</i> "Transfectomas provide novel chimeric antibodies", <i>Science</i> , September 20, 1985, pp. 1202-1207, Vol. 229.	
	R27	MURDOCK, C. <i>et al.</i> "Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues", <i>Blood</i> , October 15, 2004, pp. 2224- 2234, Vol. 104, No. 8.	
	R28	PADLAN, E.A. "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties", <i>Molecular Immunology</i> , 1991, pp. 489-498, Vol. 28, No. 4/5.	
	R29	PADLAN, E.A. "Anatomy of the antibody molecule", <i>Molecular Immunology</i> , 1994, pp. 169-217, Vol. 31, No. 3.	
	R30	PALMERI, D. <i>et al.</i> "Vascular endothelial junction-associated molecule, a novel member of the immunoglobulin superfamily, is localized to intercellular boundaries of Endothelial Cells", <i>The Journal of Biological Chemistry</i> , June 23, 2000, pp. 19139-19145, Vol. 275, No. 25.	
	R31	QUEEN, C. <i>et al.</i> "A humanized antibody that binds to the interleukin 2 receptor", <i>Proc. Natl. Acad. Sci. USA</i> , December 1989, pp. 10029-10033, Vol. 86.	
	R32	RIECHMANN, L. <i>et al.</i> "Reshaping human antibodies for therapy", <i>Nature</i> , March 24, 1988, pp. 323-327, Vol. 332, No. 24.	
	R33	TAYLOR, L.D. <i>et al.</i> "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins", <i>Nucleic Acids Research</i> , 1992, pp. 6287-6295, Vol. 20, No. 23.	
	R34	TUAILLON, N. <i>et al.</i> "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: Gene-segment use in $\mu$ and $\gamma$ transcripts", <i>Proc. Natl. Acad. Sci. USA</i> , April 1993, pp. 3720-3724, Vol. 90.	
	R35	TUAILLON, N. <i>et al.</i> "Biased utilization of D <sub>HQ52</sub> and J <sub>H4</sub> gene segments in a human Ig transgenic minilocus is independent of antigenic selection", 1994, pp. 2912-2920, Vol. 152.	
	R36	VERHOEYEN, M. <i>et al.</i> "Reshaping human antibodies: grafting an antilysozyme activity", <i>Science</i> , March 25, 1988, pp. 1534-1536, Vol. 239.	
	R37	ZEN, K. <i>et al.</i> "JAM-C is a component of desmosomes and a ligand for CD11b/CD18-mediated neutrophil transepithelial migration", <i>Molecular Biology of the Cell</i> , August 2004, pp. 3926-3937, Vol. 15.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.